Interleukin 6 as a Key Regulator of Muscle Mass during Cachexia
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Interleukin 6 (IL-6) has received significant attention for its regulatory role in muscle wasting during cachexia. This review examines the role of circulating IL-6 for decreasing muscle mass during cancer and emphasizes some of the indirect actions of IL-6 that may cause muscle wasting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 3×
“IL-6 is a member of a family of multifunctional cytokines that includes IL-11, leukemia inhibitory factor, ciliary neurotrophic factor, and cardiotrophin 1, among others (21).”
BackgroundInfluentialMuscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
Pedersen, B. K., & Febbraio, M. A. (2008) · Physiological Reviews · doi:10.1152/physrev.90100.2007 · Cited by 2,388 · cited 1×
“The physiological implications related to exercise-induced increases in circulating and skeletal muscle IL-6 have been reviewed recently and demonstrate the important regulatory role of IL-6 on metabolism and immune function during and after exercise (31).”
BackgroundMuscaritoli, M., Anker, S. D., Argilés, J., Aversa, Z., Bauer, J. M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., et al. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.12.004 · Cited by 1,732 · cited 1×
“An unintentional 10% loss of body weight over a 12-month period that is directly associated with an underlying disease is termed cachexia (28).”
BackgroundTisdale, M. J. (2009) · Physiological Reviews · doi:10.1152/physrev.00016.2008 · Cited by 1,192 · cited 4×
“There is an unequivocal agreement in the literature that muscle mass loss with cachexia involves the regulation and induction of protein degradation, protein synthesis, and apoptosis (35).”
BackgroundInfluentialDoyle, C., Kushi, L. H., Byers, T., Courneya, K. S., Demark-Wahnefried, W., Grant, B., McTiernan, A., Rock, C. L., Thompson, C., Gansler, T., et al. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.6.323 · Cited by 950 · cited 1×
“The American Cancer Society also has published suggestions for physical activity levels in cancer patients undergoing treatment and during the recovery process (12).”
BackgroundEvidence for the involvement of interleukin 6 in experimental cancer cachexia.
Strassmann, G., Fong, M., Kenney, J. S., & Jacob, C. O. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115767 · Cited by 658 · cited 4×
“It has been shown that when tumors are removed from cachectic rodents, body mass can return to normal, and circulating IL-6 levels significantly decrease (34).”
BackgroundMethodInfluentialIL-6-induced skeletal muscle atrophy
Haddad, F., Zaldivar, F., Cooper, D. M., & Adams, G. R. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01026.2004 · Cited by 612
Cancer cachexia is regulated by selective targeting of skeletal muscle gene products
Acharyya, S., Ladner, K. J., Nelsen, L. L., Damrauer, J., Reiser, P. J., Swoap, S., & Guttridge, D. C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420174 · Cited by 542
Moses, A. W. G., Slater, C., Preston, T., Barber, M. D., & Fearon, K. C. H. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601620 · Cited by 452 · cited 1×
“Others have shown that weight-losing cancer patients exhibit less physical activity than healthy controls (27).”
BackgroundA trauma‐like elevation of plasma cytokines in humans in response to treadmill running
Ostrowski, K., Hermann, C., Bangash, A., Schjerling, P., Nielsen, J. N., & Pedersen, B. K. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.889ba.x · Cited by 398 · cited 1×
“Because systemic IL-6 levels normally peak immediately after an acute bout of exercise and return to baseline levels by 2 d after exercise (30), our definition of chronic IL-6 is anything longer than this normal, physiological response of systemic IL-6 seen during exercise.”
Background
Cited by
IL-6/IL-6 receptor system and its role in physiological and pathological conditions
Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M., & Shiina, M. (2012) · Clinical Science · doi:10.1042/cs20110340 · Cited by 895
Interleukin‐6 myokine signaling in skeletal muscle: a double‐edged sword?
Muñoz‐Cánoves, P., Scheele, C., Pedersen, B. K., & Serrano, A. L. (2013) · The FEBS Journal · doi:10.1111/febs.12338 · Cited by 774
Bonetto, A., Aydogdu, T., Jin, X., Zhang, Z., Zhan, R., Puzis, L., Koniaris, L. G., & Zimmers, T. A. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00039.2012 · Cited by 463
Cancer cachexia, mechanism and treatment
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i4.17 · Cited by 434
Lutz, C. T., & Quinn, L. S. (2012) · Aging · doi:10.18632/aging.100482 · Cited by 333
White, J. P., Baynes, J. W., Welle, S. L., Kostek, M. C., Matesic, L. E., Sato, S., & Carson, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024650 · Cited by 260
“Pro-inflammatory cytokine IL-6 has been implicated in the regulation of muscle wasting during cachexia in both humans and rodents [33].”
Self-citationEpigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival
Segatto, M., Fittipaldi, R., Pin, F., Sartori, R., Dae Ko, K., Zare, H., Fenizia, C., Zanchettin, G., Pierobon, E. S., Hatakeyama, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01645-7 · Cited by 101
“Proteins (30 µ g) were resolved by 12% (for caspase-3, LC3b, interleukin-6, H3, and PTHrP), 10% (for Myc, Atrogin-1, Beclin-1, AMPK, Akt, Myostatin, ATGL, and SMAD3), and 7% (for MyHC fast, MyHC slow, Ulk, FoxO1, FoxO3, STAT3, SREBP-1, and ACC), and SDS-PAGE at 30mA (constant current) for 60min.”
InfluentialOral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.
Shadfar, S., Couch, M. E., McKinney, K. A., Weinstein, L. J., Yin, X., Rodríguez, J. E., Guttridge, D. C., & Willis, M. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.563032 · Cited by 98
Mueller, T. C., Bachmann, J., Prokopchuk, O., Friess, H., & Martignoni, M. E. (2016) · BMC Cancer · doi:10.1186/s12885-016-2121-8 · Cited by 95
“Administration of IL-6 to Apc mice induced MAfxb expression via STAT3, whereas MuRF-1 was unaltered at gene and protein levels [35].”
BackgroundThe hormetic and hermetic role of IL-6
Forcina, L., Franceschi, C., & Musarò, A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101697 · Cited by 85
“administration, local infusion or in vivo electroporation) significantly affects muscle mass, muscle protein content, and muscle growth (Bodell et al., 2009; Carson and Baltgalvis, 2010; De Benedetti et al., 1997; Pelosi et al., 2021).”
Musculoskeletal senescence: a moving target ready to be eliminated
Baar, M. P., Perdiguero, E., Muñoz-Cánoves, P., & de Keizer, P. L. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.007 · Cited by 83
“Indeed, muscle atrophy is linked to high IL-6 levels in patients with inflammatory diseases such as cancer [27].”
BackgroundAcute myotube protein synthesis regulation by IL-6-related cytokines
Gao, S., Durstine, J. L., Koh, H.-J., Carver, W. E., Frizzell, N., & Carson, J. A. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00112.2017 · Cited by 69
“Unlike the beneficial effects of IL-6 and LIF under these transient physiological conditions, long-term pathological elevation of circulating IL-6 and LIF is tightly linked with muscle wasting (12, 44, 59, 65, 66).”
BackgroundCella, P. S., Marinello, P. C., Borges, F. H., Ribeiro, D. F., Chimin, P., Testa, M. T. J., Guirro, P. B., Duarte, J. A., Cecchini, R., Guarnier, F. A., et al. (2020) · European Journal of Nutrition · doi:10.1007/s00394-019-01933-6 · Cited by 51
Metadata
- Authors
- Carson, J. A., & Baltgalvis, K. A.
- Venue
- Exercise and Sport Sciences Reviews
- Published
- 2010-10
- Volume
- 38
- Issue
- 4
- Pages
- 168-176
- ISSN
- 0091-6331 (ISSN-L)
- OpenAlex
- W2002356152
- Cited by
- 215
- References
- 37
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.